Information Provided By: 
Fly News Breaks for September 8, 2015
RHHBY, BIIB
Sep 8, 2015 | 08:29 EDT
After speaking with physicians, Bernstein believes that the growth of Biogen's (BIIB) Tecfidera is likely to be "limited," while demand for the medicine will probably continue to decline. However, the firm expects the decline to be "limited," and it predicts that changes in the MS market will probably occur gradually. Bernstein warns that Roche's (RHHBY) ocrelizumab could challenge Biogen's Tysbari for best in class status for patients with refractory or resistant disease. However, it keeps an Outperform rating on Biogen.
News For BIIB;RHHBY From the Last 2 Days
BIIB
Apr 25, 2024 | 04:58 EDT
BIIB
Apr 24, 2024 | 16:14 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
BIIB
Apr 24, 2024 | 13:04 EDT
BIIB
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BIIB
Apr 24, 2024 | 06:50 EDT
BIIB
Apr 24, 2024 | 06:48 EDT
RHHBY
Apr 24, 2024 | 06:33 EDT
RHHBY
Apr 24, 2024 | 06:30 EDT
